These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 25192691

  • 41. Electrocardiographic manifestations of hyperkalemia in hemodialysis patients.
    Nemati E, Taheri S.
    Saudi J Kidney Dis Transpl; 2010 May; 21(3):471-7. PubMed ID: 20427871
    [Abstract] [Full Text] [Related]

  • 42. Possible screening test for familial pseudohyperkalaemia.
    Leadbeatter S, O'Dowd TC.
    Lancet; 1982 Jul 10; 2(8289):103-4. PubMed ID: 6123793
    [No Abstract] [Full Text] [Related]

  • 43. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.
    Kaisar MO, Wiggins KJ, Sturtevant JM, Hawley CM, Campbell SB, Isbel NM, Mudge DW, Bofinger A, Petrie JJ, Johnson DW.
    Am J Kidney Dis; 2006 May 10; 47(5):809-14. PubMed ID: 16632019
    [Abstract] [Full Text] [Related]

  • 44. An evaluation of hyperkalemia and serum creatinine elevation associated with different dosage levels of outpatient trimethoprim-sulfamethoxazole with and without concomitant medications.
    Gentry CA, Nguyen AT.
    Ann Pharmacother; 2013 Dec 10; 47(12):1618-26. PubMed ID: 24259630
    [Abstract] [Full Text] [Related]

  • 45. The phenomenon of seasonal pseudohypokalemia: effects of ambient temperature, plasma glucose and role for sodium-potassium-exchanging-ATPase.
    Sodi R, Davison AS, Holmes E, Hine TJ, Roberts NB.
    Clin Biochem; 2009 Jun 10; 42(9):813-8. PubMed ID: 19232334
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Effects of presentation and electrocardiogram on time to treatment of hyperkalemia.
    Freeman K, Feldman JA, Mitchell P, Donovan J, Dyer KS, Eliseo L, White LF, Temin ES.
    Acad Emerg Med; 2008 Mar 10; 15(3):239-49. PubMed ID: 18304054
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Pretreatment of formula or expressed breast milk with sodium polystyrene sulfonate (Kayexalate(®)) as a treatment for hyperkalemia in infants with acute or chronic renal insufficiency.
    Thompson K, Flynn J, Okamura D, Zhou L.
    J Ren Nutr; 2013 Sep 10; 23(5):333-9. PubMed ID: 23707305
    [Abstract] [Full Text] [Related]

  • 50. Evaluation of alerts for potassium-increasing drug-drug-interactions.
    Eschmann E, Beeler PE, Zünd G, Blaser J.
    Stud Health Technol Inform; 2013 Sep 10; 192():1056. PubMed ID: 23920830
    [Abstract] [Full Text] [Related]

  • 51. [Influence of hyperkalemia on clinical decision making].
    Matsuo S, Yamamoto Y, Asano H, Takahashi H.
    Rinsho Byori; 1996 Nov 10; 44(11):1087-92. PubMed ID: 8953941
    [Abstract] [Full Text] [Related]

  • 52. Effect of blood collection tubes on the incidence of artifactual hyperkalemia on patient samples from an outreach clinic.
    Babic N, Zibrat S, Gordon IO, Lee CC, Yeo KT.
    Clin Chim Acta; 2012 Oct 09; 413(19-20):1454-8. PubMed ID: 22698439
    [Abstract] [Full Text] [Related]

  • 53. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?
    Raebel MA, McClure DL, Chan KA, Simon SR, Feldstein AC, Lafata JE, Andrade SE, Gunter MJ, Nelson WW, Roblin D, Platt R.
    Ann Pharmacother; 2007 Feb 09; 41(2):193-200. PubMed ID: 17284506
    [Abstract] [Full Text] [Related]

  • 54. Hyperkalaemia in a Thai man.
    Smit WJ.
    Lancet; 1999 Oct 02; 354(9185):1182. PubMed ID: 10513721
    [Abstract] [Full Text] [Related]

  • 55. Life-threatening drug-associated hyperkalemia: a retrospective study from laboratory signals.
    Noize P, Bagheri H, Durrieu G, Haramburu F, Moore N, Giraud P, Galinier M, Pourrat J, Montastruc JL.
    Pharmacoepidemiol Drug Saf; 2011 Jul 02; 20(7):747-53. PubMed ID: 21438068
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M, Takada M, Hirooka K, Isobe F, Yasumura Y.
    J Clin Pharm Ther; 2005 Dec 02; 30(6):603-10. PubMed ID: 16336294
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59. Pseudohyperkalaemia.
    Kerr DJ, McAlpine LG, Dagg JH.
    Br Med J (Clin Res Ed); 1985 Sep 28; 291(6499):890-1. PubMed ID: 3931755
    [Abstract] [Full Text] [Related]

  • 60. Follow-up of markedly elevated serum potassium results in the ambulatory setting: implications for patient safety.
    Moore CR, Lin JJ, O'Connor N, Halm EA.
    Am J Med Qual; 2006 Sep 28; 21(2):115-24. PubMed ID: 16533903
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.